CClinicalTrials.gg
RecruitingNCT06536296Updated Mar 25, 2026

The Impact of Music Medicine on Preterm Brain Development and Behavior

An interventional study of Music and Music and parent voice in Infant Development, Language Development and Prematurity, sponsored by Brigham and Women's Hospital. Recruiting at 2 sites in United States. Open to participants aged 24 Weeks to 30 Weeks. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started May 2025; still recruiting 1 year 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
243
Allocation
Randomized
Ages
24 Weeks to 30 Weeks
Sex
All
01

Study summary

The investigators are conducting a two-site randomized control trial with the aim of defining the impact of music (M) without or with parent voice (MPV) on very preterm infants' acute and cumulative stress, intranetwork connectivity on term brain MRI, and language and other neurodevelopmental outcomes at two years corrected age. This is based on the hypothesis that infants in MPV arm are expected to experience the greatest benefit compared with infants receiving standard care.

Read the detailed description

Preterm birth remains the leading cause of death for children under five. For survivors, it also accounts for high morbidity and substantial physical, psychosocial, emotional, and financial burden for individuals, families, and communities. The impairments span over multiple domains, with language difficulties affecting about half of surviving children. Evidence indicates that preterm birth has significant impacts on long-term functioning, yet primary prevention of preterm birth is presently not feasible. It is therefore imperative to prioritize early interventions to mitigate these adverse long-term effects on child and family outcomes.

Very preterm (VP) infants, i.e., those born below 32 weeks gestational age (GA) typically spend 2-4 months hospitalized in the Neonatal Intensive Care Unit (NICU) before reaching term-equivalent age (TEA). During this time, the preterm brain nearly quadruples in volume and is highly sensitive to both positive and negative environmental experiences. Yet, during this period, VP infants must also receive life-saving intensive medical care in the sensory-atypical environment of the NICU. From an auditory perspective, this atypical environment comprises loud equipment sounds at volumes far exceeding recommended levels, silence, and a paucity of human interaction. One domain of neurosensory experience is the auditory environment, comprised predominantly of non-meaningful, high-frequency/ high decibel equipment sounds, and silence. The deprivation of VP infants from enriching auditory experiences (parental voice, infant-directed language) combined with the constant influx of high frequency/high decibel sounds (alarms and electronic noise) can induce chronic stress and negatively impact auditory and other areas of cortical development.

For preterm infants who have not yet reached term-equivalent age (TEA), the NICU hospitalization is a critical window for developmental adaptability to experience during a highly sensitive period of brain development. There are two key pathways whereby music and voice therapy in the VP infant are thought to have benefit - stress reduction and auditory enrichment. Recent work indicates that music therapy may reduce the immediate stress experienced by VP infants, with evidence emerging on its impact to improve neurodevelopmental outcomes. Prior studies have been limited due to small size, variability of music exposures, inconsistent study design and outcome measures. Further, most studies explored exposure-outcome associations, without mechanistic investigation. One study showed improved white matter maturation in acoustic radiations, larger amygdala volumes, and enhanced functional connectivity brain magnetic resonance imaging (MRI) after early music exposures. These suggests that early music exposure may enhance auditory cortex development and reduce stress (amygdala) in VP infants.

While small studies inform these hypotheses, a large, randomized trial is necessary to test them more rigorously. Our own center's pilot study demonstrated that a music condition with low, repetitive, and rhythmically consistent entrainment stimulus was associated with improved physiologic state after the exposure. Based on these data, the investigators plan to further develop an individualized intervention encompassing evidence-based musical elements onto which parental voice will be carefully layered. The aim of this proposal is to conduct a randomized trial to determine the effects of a protocolized music-based intervention (MBI) with and without parental voice on stress reduction, early brain structure and function, and neurodevelopmental outcomes.

The investigators propose to address this knowledge gap in a large, two-center randomized controlled trial (RCT), employing a novel MBI tailored based on available preliminary data and inclusive of musical and non-musical elements to facilitate parent engagement, with comprehensive evaluation of relevant clinical, neuroimaging, and neurodevelopmental outcomes of VP infants up to two years of age. The impact of this work will be two-fold: this proposal will 1) generate rigorous evidence to specifically support the integration of music medicine as a therapeutic approach for VP infants in the NICU, and 2) strengthen the evidence base for neurosensory interventions for hospitalized infants, which will shift the framework of care in the NICU by leveraging developmental care interventions to optimize the outcomes of VP infants.

02

Conditions studied

  • Infant Development
  • Language Development
  • Prematurity
  • Stress

Browse trials for

Keywords

  • Preterm
  • Neurodevelopment
  • Music-based Intervention
03

In context

Premature Birth

2,554 studies on the registry are indexed under Premature Birth; 498 are open to participants now.

This study's planned enrollment of 243 is above the median of 84 across 1,689 interventional studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

Brigham and Women's Hospital is the lead sponsor of 1,236 studies on the registry; 224 are open to participants now.

Of its 116 completed or terminated interventional studies of FDA-regulated products, 64 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
24 Weeks to 30 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Very preterm infants born between 24+0 and 30+6 weeks' gestational age (GA) from 2 level III NICUs (Brigham and Women's Hospital, Boston, MA and Yale New Haven, CT)
  • Infants who are medically stable per the clinical care team

Exclusion criteria

Exclusion Criteria:

  • Infants with major genetic or congenital anomalies known to be associated with developmental delay
  • Infants with severe brain injury (such as intraparenchymal hemorrhage, severe white matter injury)
  • Infants who are severely ill infants for whom MBI is not feasible
  • Infants of parents who cannot complete questionnaires in English or Spanish.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
243 participants (estimated)

Study arms

  • Experimental
    Music

    We will create three recordings with increasing complexity for each infant. For each infant developmental stage (32, 34, 36+ weeks PMA), Music Therapists (MTs) in both units will present parents with a curated list of 8-10 musically comparable, familiar lullabies to select from. Songs will be available in different languages reflective of patient diversity, with rhythm, tempo, pitch range/ change, instrumentation, melody, harmony selected drawing on available evidence, including BWH NICU pilot data. Timing: MBI to be administered after regular NICU "care and feeding" times, which are typically considered stressful times for infants. The goal of the intervention will be to provide a calming and relaxing experience to the infant as they "settle" back to sleep after handling times. Music delivery will occur via infant-adapted headphones to facilitate blinding.

    Other: Music

  • Experimental
    Music and parent voice

    The selected lullabies will be pre-recorded by the MT as described above to include a guitar accompaniment track, and a separate vocal track with the MT singing along, in two separate keys to allow variation for parent voice range and comfort. Parents will be invited to sing along with the recorded track of MT singing, and MT will later remove the MT-voice recording track so only the parent voice will be heard with the guitar in the final recording. Timing: MBI to be administered after regular NICU "care and feeding" times, which are typically considered stressful times for infants. The goal of the intervention will be to provide a calming and relaxing experience to the infant as they "settle" back to sleep after handling times. Music delivery will occur via infant-adapted headphones to facilitate blinding.

    Other: Music and parent voice

  • Active comparator
    Reference/ Standard of care

    These are infants recruited in the study who will receive the unit standard of care. They will be listening to the NICU ambient noise via infant-adapted headphones but will not receive any music intervention.

    Other: Standard Care

Interventions

  • OtherMusic

    Arm 1: Music only

    Also known as: Arm 1: Music

  • OtherMusic and parent voice

    Arm 2: Music and parent voice

    Also known as: Arm 2: Music and parent voice

  • OtherStandard Care

    Standard Care

    Also known as: Arm 3: Standard Care

06

What researchers measure

Primary outcomes

  1. Bayley-4 language performance (SA3 primary outcome)

    Study patients Language performance measured on the Bayley-4 at 2 years corrected age

    Time frame: 2 years corrected age

  2. Amygdala volume on MRI (SA1a, primary outcome)

    Amygdala volume as a proxy of cumulative stress measured on term-equivalent brain MRI

    Time frame: At term-equivalent (~ 3 months of age), 37-41 weeks postmenstrual age (PMA)

  3. Intranetwork connectivity in Salience and Language networks (SA2a, primary outcome)

    We will measure the intranetwork connectivity in Salience and Language networks in infants exposed to music and music with parent voice compared those in SC arm at term-equivalent

    Time frame: Term-equivalent (~ 3 months of age), 37-41 weeks postmenstrual age (PMA)

Secondary outcomes

  1. Infant physiology - oxygen saturation

    We will record infant physiologic vital signs (i.e. oxygen saturation) from infants' bedside monitor around each study intervention

    Time frame: From enrollment to term-equivalent 37-41 weeks PMA

  2. Infant physiology - respiratory rate

    We will record infant physiologic vital signs (i.e. respiratory rate) from infants' bedside monitor around each study intervention

    Time frame: From enrollment to term-equivalent 37-41 weeks PMA

  3. Infant physiology - heart Rate

    We will record infant physiologic vital signs (i.e. heart rate) from infants' bedside monitor around each study intervention

    Time frame: From enrollment to term-equivalent 37-41 weeks PMA

  4. Telomere length

    Assess infant premature aging at term-equivalent by measurement of telomere length on blood samples

    Time frame: At enrollment and term-equivalent 37-41 weeks PMA

  5. Neurodevelopmental assessment - cognitive outcomes

    Study patients' cognitive performance measured on the Bayley-4 assessment at 2 years corrected age

    Time frame: 2 years corrected age

  6. Neurodevelopmental assessment - motor outcomes

    Study patients' motor performance measured on the Bayley-4 assessment at 2 years corrected age

    Time frame: 2 years corrected age

  7. Neurodevelopmental assessment - child behavior outcomes

    Study patients' behavioral performance measured on the Child Behavior Checklist at 2 years corrected age

    Time frame: 2 years corrected age

  8. Brain development

    Brain development and injury classified using the established Kidokoro scoring system applied to term-equivalent brain MRI

    Time frame: Term-equivalent age - 37-41 weeks PMA

  9. Parent stress

    Assessment of parent stress (Parental Stressor Scale) using a standardized survey of families of study infants

    Time frame: From term-equivalent age to 2 years corrected age

  10. Parent anxiety and depression

    Assessment of parent anxiety and depression (Hospital Anxiety and Depression Scale) using one standardized survey that provides a combined score

    Time frame: From term-equivalent age to 2 years corrected age

  11. Infant Neurobehavior

    We will assess infant neurobehavior using the Hammersmith Neonatal Neurological Examination at term-equivalent age 37-41 weeks PMA

    Time frame: Term-equivalent 37-41 weeks PMA

07

Study locations

1 of 2 sites recruiting
  • Yale New Haven Hospital
    New Haven, Connecticut 06510, United States
    Not yet recruiting
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06536296
Lead sponsor
Brigham and Women's Hospital
Collaborators
Yale New Haven Health System Center for Healthcare Solutions
Responsible party
Carmina Erdei, MD (Neonatologist, Brigham and Women's Hospital) — Principal investigator
First posted
Aug 2, 2024
Start date
May 19, 2025
Primary completion
Aug 30, 2030 (estimated)
Completion
Mar 1, 2031 (estimated)
Last update
Mar 25, 2026

Study contacts

Carmina Erdei, MD
Contact
cerdei@bwh.harvard.edu
6174620202
Isabella J Lawandy
Contact
ilawandy@bwh.harvard.edu
4014901670

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion